At 72 weeks, tirzepatide resulted in 20.2% average weight loss compared to 13.7% with semaglutide
Choose from the 18-IV menu, or let the physician recommend a formula based on your goals, labs, and any recent symptoms
[1] [2] Despite this research interest, retatrutide has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for clinical use in the United Kingdom
Patients should maintain a symptom diary, attend scheduled follow-up appointments, and report persistent or worsening side effects
This means that if you decide to try them together, it is essential to listen to your body and adjust the dosage accordingly
We use high quality boxes and insulated mailers to confidently deliver our products to your door